LNS-8801 is under clinical development by Linnaeus Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LNS-8801’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LNS-8801 is under development for the treatment of solid tumors including melanoma, pancreatic ductal adenocarcinoma, lymphoma, non-small cell lung cancer, recurrent head and neck squamous cell cancer, cutaneous, colorectal cancer, metastatic uveal melanoma and stage IIB to stage IV melanoma. The drug candidate acts by targeting G protein-coupled estrogen receptor (GPER). It is administered through oral route.
Linnaeus Therapeutics overview
Linnaeus Therapeutics is a development stage biotech company. It identifies and develops small molecule agents for the treatment of cancer. The company focuses on developing treatments for various cancers, including melanoma, pancreatic ductal adenocarcinoma, non-small cell lung cancer and colon carcinomas. Its lead compound LNS8801 is an agonist of G protein-coupled estrogen receptor (GPER), which has activity across a wide range of preclinical cancer models. Linnaeus Therapeutics is headquartered in Haddonfield, New Jersey, the US
For a complete picture of LNS-8801’s drug-specific PTSR and LoA scores, buy the report here.